AGP Executive Report
Last update: 7 hours agoDrug Policy & Vaccines: Trump says he’ll demand drugmakers split vaccines into five smaller doses over six months, arguing it could cut autism rates—an idea experts warn could delay protection and lacks new science. Critical Care Pain: A new ICU study finds over three-quarters of critically ill patients report at least moderate pain, with pain persisting across follow-up and linked to worse outcomes. Rare Disease Treatment: FDA approved Ultragenyx’s Fayuvi as the first pediatric gene therapy for Sanfilippo syndrome type A (ages 2–5). Pharma Business Moves: Lisata Therapeutics is acquiring Marea Therapeutics, while mAbxience partners with Sandoz on a hemophilia A biosimilar. Healthcare Costs: A Commonwealth Fund survey finds medical debt affects about one-third of privately insured adults, hitting lower-income and minority groups hardest. Public Health Response: Nepal expanded oral cholera vaccination in flood-affected areas, alongside measles monitoring and tetanus-diphtheria shots for responders and injured people. AI in Oncology: Only 19% of community oncologists use AI predictive models, despite broad interest in AI’s potential to improve access.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Japan Approves T-DXd Combo and Dato-DXd for First-Line Metastatic Breast Cancer]]>](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cf367ec503f0a59214d7b86ee585d8c613dfa25f-490x264.jpg)
